Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,127
  • Shares Outstanding, K 170,738
  • Annual Sales, $ 126,330 K
  • Annual Income, $ -113,720 K
  • EBIT $ -140 M
  • EBITDA $ -132 M
  • 60-Month Beta 2.13
  • Price/Sales 0.98
  • Price/Cash Flow N/A
  • Price/Book 6.19
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.14
  • Most Recent Earnings $-0.33 on 11/13/24
  • Next Earnings Date 03/04/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 171.63% ( +29.68%)
  • Historical Volatility 78.54%
  • IV Percentile 43%
  • IV Rank 23.12%
  • IV High 652.30% on 04/17/24
  • IV Low 27.12% on 01/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 907
  • Volume Avg (30-Day) 450
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 63,921
  • Open Int (30-Day) 64,137

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.19
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +46.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8033 +5.81%
on 12/31/24
1.0000 -15.00%
on 12/23/24
+0.0267 (+3.24%)
since 12/06/24
3-Month
0.5406 +57.23%
on 11/18/24
1.0100 -15.84%
on 12/02/24
+0.0787 (+10.20%)
since 10/08/24
52-Week
0.5400 +57.41%
on 04/19/24
2.0500 -58.54%
on 01/09/24
-0.7100 (-45.51%)
since 01/08/24

Most Recent Stories

More News
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

MCRB : 0.8500 (-2.30%)
Seres Therapeutics to Present at J.P. Morgan Healthcare Conference, Highlighting SER-155 Breakthrough Therapy Designation

Seres Therapeutics will present at the J.P. Morgan Healthcare Conference, focusing on SER-155's potential to reduce bloodstream infections.Quiver AI SummarySeres Therapeutics, Inc. has announced that CEO...

MCRB : 0.8500 (-2.30%)
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

MCRB : 0.8500 (-2.30%)
Seres Therapeutics Announces FDA Breakthrough Therapy Designation for SER-155 Following Promising Phase 1b Clinical Results

The FDA granted SER-155 Breakthrough Therapy designation for reducing bloodstream infections in allo-HSCT patients, supported by promising Phase 1b clinical data.Quiver AI SummarySeres Therapeutics announced...

MCRB : 0.8500 (-2.30%)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

MCRB : 0.8500 (-2.30%)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

MCRB : 0.8500 (-2.30%)
Seres Therapeutics: Q3 Earnings Snapshot

Seres Therapeutics: Q3 Earnings Snapshot

MCRB : 0.8500 (-2.30%)
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

MCRB : 0.8500 (-2.30%)
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

MCRB : 0.8500 (-2.30%)
Seres Therapeutics: Q2 Earnings Snapshot

Seres Therapeutics: Q2 Earnings Snapshot

MCRB : 0.8500 (-2.30%)

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 0.9115
2nd Resistance Point 0.8952
1st Resistance Point 0.8726
Last Price 0.8500
1st Support Level 0.8337
2nd Support Level 0.8174
3rd Support Level 0.7948

See More

52-Week High 2.0500
Fibonacci 61.8% 1.4732
Fibonacci 50% 1.2950
Fibonacci 38.2% 1.1168
Last Price 0.8500
52-Week Low 0.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar